High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 12, 1903-1912
Abstract
Purpose: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma. Patients and Methods: We collected clinical and pathological data of 41 cases of newly diagnosed HGBL, NOS, and analyzed diagnosis, prognosis and treatment to examine progression-free survival (PFS) and overall survival (OS). Results: Among the 41 cases studied, the median PFS was 6.0 months and the median OS was 18.0 months. Compared with patients treated with the R-CHOP regimen, patients treated with a high-intensity chemotherapy (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS (PFS: chi(2)=4.173, P=0.041; OS: chi(2 )=5.200, P=0.023). A subgroup analysis showed that the OS for the double-expressor lymphoma (DEL) was inferior to that for the non-DEL (chi(2)=4.563, P=0.033), and this trend was also seen for the single-hit lymphoma with MYC rearrangement (SHL) and the non-SHL (chi(2)=4.955, P=0.026). Patients with low International Prognostic Index (IPI) scores (<= 2) had better survival rates than those with high scores (>2) (PFS: chi(2) =6.482, P=0.011; OS: chi(2)=10.156, P=0.001). Conclusion: HGBL, NOS is associated with a high degree of malignancy, short survival period, and substantial extranodal involvement. High-intensity chemotherapy may improve patient prognosis. While IPI scores statistically correlated with the prognosis, SHL and DEL correlated with an inferior survival rate. New and improved treatments will be needed for HGBL, NOS.Keywords
This publication has 31 references indexed in Scilit:
- Stratification by MYC expression has prognostic impact in MYC translocated B‐cell lymphoma—Identifies a subgroup of patients with poor outcomeEuropean Journal of Haematology, 2019
- Advances in pathological understanding of high-grade B cell lymphomasExpert Review of Hematology, 2018
- Diagnosis and classification of hematologic malignancies on the basis of geneticsBlood, 2017
- High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphomaBlood Reviews, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHCHematology-American Society Hematology Education Program, 2014
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphomaBritish Journal of Haematology, 2011
- Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphomaCancer, 2011
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007